Companies › Chendu DIAO Pharmaceutical Group
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DA-302168S GLP-1R agonist | GLP1R | Phase 3 | Overweight and Obesity | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07629544 | DA-302168S | Phase 3 | Overweight and Obesity | Metabolic and endocrine | Jul 2027 |
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Beijing QL Biopharmaceutical Beijing Dongfang Biotech Kailera Fresenius Kabi
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.